185030-18-6

Basic information

• Product Name: N-(piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenylacetamide
• Synonyms: N-(piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenylacetamide
• CAS NO: 185030-18-6
• Molecular Weight: 302.417
• Mol File: 185030-18-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenylacetamide(185030-18-6)
• EPA Substance Registry System: N-(piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenylacetamide(185030-18-6)

Safety Data

• Hazardous Substances Data: 185030-18-6(Hazardous Substances Data)

Upstream product

• 189819-75-8 4-amino-1-(t-butoxycarbonyl)piperidine monohydrochloride 
• 144-55-8 sodium hydrogencarbonate 
• 427-49-6 2-cyclopentyl-2-hydroxy-2-phenylacetic acid 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 186755-46-4 N-(1-benzyl-piperidin-4-yl)-2-cyclopentyl-2-hydroxy-2-phenyl-acetamide 

Downstream Products

• 244277-89-2 (+/-)-J 104129 

Relevant articles and documents

Substituted piperidine derivatives as muscarinic M3 receptor antagonists

PCT No. PCT/JP96/02904 Sec. 371 Date Apr. 9, 1998 Sec. 102(e) Date Apr. 9, 1998 PCT Filed Oct. 7, 1996 PCT Pub. No. WO97/13766 PCT Pub. Date Apr. 17, 1997This invention provides substituted heteroaromatic ring derivatives which are represented by a genera

Fluorine-containing 1,4-disubstituted piperidine derivatives

Novel fluorine-containing 1,4-disubstituted piperidine derivatives, represented by general formula ?I! STR1 such as, for example, (2R)-N-?1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl!-2-?(1R)-3,3-difluorocyclopentyl!-2-hydroxy-2-phenylacetamide or pharmaceutically acceptable salt thereof, are potent and selective antagonists for muscarinic M3 receptors with little side effects. The compounds of formula ?I! exhibit excellent oral activity, duration of activity and pharmacolkinetics. They are useful for treatment and prophylaxis of respiratory diseases, such as chronic obstructive pulmonary diseases; urinary diseases, such as urinary incontinence; and digestive diseases, such as irritable bowel syndrome, and motion sickness.